Molecular Pathogenesis and Evolving Precision Medicine in Leukemia

Leukemia is a complex and heterogeneous group of malignancies that arise within the hematological system, originating in the bone marrow. It is fundamentally characterized by the uncontrolled proliferation and accumulation of immature, non-functional white blood cells, which disrupt normal hematopoiesis and leads to classic symptoms of infection, anemia, and bleeding. This overview examines the molecular mechanism of disease, diagnostic evolution, and therapeutic advancements. The pathogenesis is not driven by a single genetic mutation but rather by a collaborative genetic lesion that affect cellular growth, differentiation, and cell death. Diagnostically, the field has progressed from traditional morphology and cytogenetics to incorporate advanced molecular profiling. The adoption of (Next-generation Sequencing) NGS allows for the comprehensive identification of driver mutations and prognostic markers, while digital PCR and flow cytometry provide effective and sensitive tools for monitoring minimal residual disease (MRD). The therapeutic ways have evolved significantly, shifting from conventional chemotherapy and radiation towards the modern management which guided by the individual genetic profile of a patients leukemia. The future of leukemia treatment lies in the deeper integration of continuous, non-invasive monitoring tools like liquid biopsy, which analyzes circulating tumour DNA from a simple blood draw. By combining this dynamic data with multi-omics analyses and artificial intelligence, clinicians aim to formulate highly dynamic and adaptable treatment strategies. The goal is to overcome drug resistance, prevent relapse, and to cure all subtype of leukemia.